Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06060600 · ClinicalTrials.gov registry record
A Retrospective Analysis of Suramin Treatment for Stage 1 TBR
A clinical trial of Trypanosoma Brucei Rhodesiense; Infection, sponsored by Paxmedica.
- Completed
- Registry status
- 345
- Enrollment target
- 1
- Study location
NCT06060600 is a study of Trypanosoma Brucei Rhodesiense; Infection that has completed, run by Paxmedica. The registered enrollment target is 345 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06060600, a study of Trypanosoma Brucei Rhodesiense; Infection, has completed, sponsored by Paxmedica.
- COMPLETED
- Registry status
- 345 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will include TBR HAT patients treated with suramin between 2000 and 2020 at three sites in Uganda and Malawi A natural history cohort composed of source data from approximately 200 patients from a published epidemiological study will be used as a comparator. This study's objectives are to evaluate the efficacy and safety of suramin in the Stage 1 treatment of TBR HAT.
Conditions Studied
Study Locations (1)
New York
- PaxMedica - Tarrytown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2023-01-02 |
| Est. Completion | 2023-08-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06060600
The ClinicalTrials.gov registry entry for NCT06060600 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Paxmedica, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Trypanosoma Brucei Rhodesiense; Infection appearing as the primary indexed condition, and to 0 interventions.
NCT06060600 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06060600 about?
NCT06060600 is a clinical study titled "A Retrospective Analysis of Suramin Treatment for Stage 1 TBR". The study will include TBR HAT patients treated with suramin between 2000 and 2020 at three sites in Uganda and Malawi A natural history cohort composed of source data from approximately 200 patients from a published epidemiological study will be used as a comparator. This study's objectives are to...
What is the current status of trial NCT06060600?
This trial is currently completed. The enrollment target is 345 participants. The study started on 2023-01-02. Estimated completion is 2023-08-02.
What conditions does trial NCT06060600 study?
This clinical trial studies the following conditions: Trypanosoma Brucei Rhodesiense; Infection.
Who is sponsoring clinical trial NCT06060600?
This trial is sponsored by Paxmedica, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06060600 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.